hs-CRP (High-Sensitivity C-Reactive Protein)

High-sensitivity C-reactive protein (hs-CRP) is a liver-produced acute-phase protein that rises with systemic inflammation, and even mildly elevated baseline levels predict future cardiovascular events and death in people with no active infection. The claim rests on decades of cohort data linking hs-CRP, measured in a resting, healthy state, to atherosclerosis progression and mortality independent of cholesterol levels.

A 2017 meta-analysis pooling 83,995 participants across 14 prospective studies found that comparing the highest to lowest hs-CRP category, the pooled risk ratio was 2.03 (95% CI 1.65-2.50) for cardiovascular mortality and 1.75 (95% CI 1.55-1.98) for all-cause mortality [1]. The cancer-mortality association (RR 1.25) held in men but not women in subgroup analysis, an inconsistency the authors flagged as needing more study [1]. The JUPITER trial (rosuvastatin in people with normal LDL but elevated hs-CRP) showed statin therapy targeting this inflammatory profile reduced cardiovascular events, supporting hs-CRP as more than a passive marker, though JUPITER tested a statin, not an isolated hs-CRP-lowering strategy.

How to measure it: a standard fasting or non-fasting blood draw processed with a high-sensitivity immunoassay, distinct from a standard CRP test that lacks the sensitivity to distinguish sub-10 mg/L differences relevant to cardiovascular risk [2][4]. Guidelines classify under 1.0 mg/L as low risk, 1.0-3.0 mg/L as average risk, and above 3.0 mg/L as high risk, though acute illness, injury, or infection can transiently spike levels 100-fold or more, so testing should happen when clinically well and ideally repeated to confirm a stable baseline [3].

How to intervene on it: weight loss, smoking cessation, omega-3 fatty acids, and statins all lower hs-CRP in randomized trials to varying degrees; the strongest single-agent effect comes from statins, which lower both LDL and hs-CRP. Canakinumab, an anti-inflammatory antibody tested in the CANTOS trial, lowered hs-CRP and cardiovascular events without lowering LDL, direct evidence that the inflammatory pathway itself, not just cholesterol, drives risk.

Critics note hs-CRP is a nonspecific marker: obesity, arthritis, gum disease, and poor sleep all raise it, so an elevated single reading does not point to a specific cause, and population-level risk-ratio data does not tell an individual patient which upstream driver to fix [3]. Some cardiologists argue ApoB and Lp(a) provide more actionable, structurally specific risk information than hs-CRP for a given patient. Bryan Johnson's Blueprint dashboard tracks hs-CRP as one routine panel item, an n=1 self-report [5][6].

The plain takeaway: hs-CRP is a well-validated, inexpensive marker of a global cardiovascular and mortality risk driven partly by chronic low-grade inflammation, useful for risk stratification alongside lipids, but nonspecific enough that a high reading calls for finding the underlying driver rather than treating the number in isolation.